Update shared on 07 Nov 2025
Narrative Update on Biovica International: Analyst Price Target Adjustment
Analysts have maintained their price target for Biovica International at SEK 1.20, which reflects continued confidence in the company’s growth outlook despite minor adjustments to underlying financial assumptions.
Valuation Changes
- The Fair Value estimate remains steady at SEK 1.20, with no change from the previous analysis.
- The Discount Rate has risen slightly from 4.997% to 5.12%.
- The Revenue Growth projection is essentially unchanged, remaining near 197.79%.
- The Net Profit Margin continues to be stable, with a marginal increase from 1.25% to 1.25%.
- The future P/E ratio has inched up from 42.77x to 42.92x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.